EUVIMEDObjevte EUVIMED
Crossref

Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator

Fatima M Ezzeddine iD, Jee Won Jennifer Shin, Konstantinos C Siontis iD, Ammar M Killu iD, John Giudicessi iD, Michael J Ackerman iD, Abhishek J Deshmukh iD, Gurukripa N Kowlgi iD, Malini Madhavan iD, Christopher J McLeod, Samuel J Asirvatham iD, Freddy Del-Carpio Munoz iD

Journal of Cardiovascular Electrophysiology · 2025

DOI: 10.1111/jce.16612 ↗

At a glance

Journal article in Journal of Cardiovascular Electrophysiology, 2025. Written by Fatima M Ezzeddine and 11 co-authors. Institution: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Defibrillators, Implantable, Mitral Valve, Electric Countershock, Death, Sudden, Cardiac. 21 references. Funded by: The authors received no specific funding for this work..

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Mitral annular disjunction (MAD) carries an increased risk of complex ventricular arrhythmias, which can lead to sudden cardiac death. Many of these patients undergo implantable cardioverter defibrillator (ICD) implantation, but their ICD outcomes are not known.

Objective

The aim of this study was to assess the outcomes of ICD implantation and the predictors of appropriate ICD therapies in patients with MAD.

Methods

The study included patients with MAD who underwent ICD implantation. Clinical, electrocardiographic, cardiac imaging, and device therapy data were collected.

Results

Forty‐nine patients with MAD and ICD were included. Median age was 49 (21) years, and 29 (59%) were female. 13 (27%) patients underwent ICD implantation for primary prevention and 36 (73%) patients for secondary prevention. Over a median follow‐up of 27.3 (35.3) months, 23 (47%) patients received ICD therapies. 18 (37%) patients had appropriate ICD therapies, and 5 (10%) patients had inappropriate ICD shocks. Median time to first appropriate therapy was 22.3 (63.3) months. In patients with a secondary prevention ICD indication, the rate of appropriate ICD therapies was 44%, while in patients with a primary prevention ICD indication, it was 15%. Among patients with appropriate ICD therapies, the first therapies were delivered for monomorphic ventricular tachycardia (VT) in 7 (39%) patients and polymorphic VT or ventricular fibrillation (VF) in 11 (61%) patients. Patients with appropriate ICD therapies were more likely to have a history of SCA ( p = 0.003) and/or low left ventricular ejection fraction (LVEF) ( p = 0.022) before ICD implantation as compared to patients without appropriate ICD therapies.

Conclusions

In our cohort of patients with MAD and ICD, appropriate ICD therapies were common. Most appropriate ICD therapies were delivered for polymorphic VT or VF. Larger studies are needed to elucidate the mechanisms of VAs and refine risk stratification in MAD.

Subjects

MeSH terms (MEDLINE)

Defibrillators, ImplantableMitral ValveElectric CountershockDeath, Sudden, CardiacPrimary PreventionTachycardia, VentricularHeart Valve DiseasesHumansFemaleMaleMiddle AgedTreatment OutcomeRisk FactorsTime FactorsAdultRetrospective StudiesSecondary PreventionAged

Author keywords

ICD dischargedefibrillatormitral annular disjunctionmitral valvemitral valve prolapseventricular arrhythmia

Authors and institutions

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Mayo Clinic Alix School of Medicine, Rochester, Minnesota, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
  • Department of Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Clinical Anatomy, Mayo Clinic, Rochester, Minnesota, USA.

ORCID profiles: Fatima M Ezzeddine, Konstantinos C Siontis, Ammar M Killu, John Giudicessi, Michael J Ackerman, Abhishek J Deshmukh, Gurukripa N Kowlgi, Malini Madhavan, Samuel J Asirvatham, Freddy Del-Carpio Munoz

Funding

  • The authors received no specific funding for this work.

Cite

APA

Ezzeddine, F. M., Shin, J. W. J., Siontis, K. C., Killu, A. M., Giudicessi, J., Ackerman, M. J., Deshmukh, A. J., Kowlgi, G. N., Madhavan, M., McLeod, C. J., Asirvatham, S. J., & Munoz, F. D. (2025). Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16612

Vancouver

Ezzeddine FM, Shin JWJ, Siontis KC, Killu AM, Giudicessi J, Ackerman MJ, et al. Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.16612

BibTeX
@article{Ezzeddine2025,
  author = {Ezzeddine, Fatima M and Shin, Jee Won Jennifer and Siontis, Konstantinos C and Killu, Ammar M and Giudicessi, John and Ackerman, Michael J and Deshmukh, Abhishek J and Kowlgi, Gurukripa N and Madhavan, Malini and McLeod, Christopher J and Asirvatham, Samuel J and Munoz, Freddy Del-Carpio},
  title = {Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  doi = {10.1111/jce.16612}
}
Start for free →